Relmada Therapeutics
RLMD
NASDAQ
IPO2014
about RLMD
Relmada Therapeutics is a biotechnology company focused on developing innovative treatments for central nervous system disorders, with its lead product candidate REL-1019 targeting interleukin-1β (IL-1β) for potential use in neurodegenerative diseases.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $6.41 | $7.41 | $5.80 | $326.33M | 42.98M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.30 | n/a | n/a | 0% | 0% | 0% |